Factor V Leiden and sepsis: Proof positive or phenomenology?

Critical Care Medicine

Volumn 34, Issue 8, 2006, Pages 2254-2255

  Parker, Robert I ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Risk of mortality; Sepsis; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5; PROTEIN C;

EDITORIAL; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; INCIDENCE; MORTALITY; NONHUMAN; PHENOMENOLOGY; PRIORITY JOURNAL; SEPSIS; ANIMAL; DISEASE MODEL; GENETICS; HETEROZYGOTE; MICROBIOLOGY; MOUSE; NOTE; PHYSIOLOGY; POINT MUTATION;

ANIMALS; DISEASE MODELS, ANIMAL; FACTOR V; HETEROZYGOTE; MICE; POINT MUTATION; PROTEIN C; SEPSIS;

EID: 33748098514     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000229679.01590.4D     Document Type: Editorial

References (16)

1. Bertina RM, Koeleman BPC, Koster T, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67
2. Rosendaal FR: Risk factors for venous thrombosis: Prevalence, risk and interaction. Semin Hematol 1997; 34:171-187
3. Bertina RM: Molecular risk factors for thrombosis. Thromb Haemost 1999; 82:601-609
4. Yan SB, Nelson DR: Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 2004; 32(Suppl):S239-S246
5. Weiler H, Kerlin B, Lytle MC: Factor V Leiden polymorphism modifies sepsis outcome: Evidence from animal studies. Crit Care Med 32(Suppl):S233-S238
6. Kerlin BA, Yan SB, Isermann NH, et al: Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102:3085-3092
7. Weiler-Guettler H, Christie PD, Beeler DL, et al: A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998; 101:1983-1991
8. Benfield TL, Dahl M, Nordestgaarsd BG, et al: Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: A population-based study. J Infect Dis 2005; 192:1851-1857
9. Brüggemann LW, Schoenmakers SHHF, Groot AP, et al: Role of the FV Leiden mutation in septic peritonitis assessed in FV Leiden transgenic mice. Crit Care Med 2006; 34:2201-2206
10. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 2005; 131:417-430
11. Esmon CT: The protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29(Suppl):S48-S52
12. Macias WL, Nelson DR: Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 32(Suppl):S223-S228
13. Spiel AO, Firbas C, Mayr FB, et al: The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia. Thromb Haemost 2005; 94:1148-1155
14. Aird WC: Endothelium as an organ system. Crit Care Med 2004; 32(Suppl):S271-S279
15. Aird WC: The role of the endothelium in severe sepsis and the multiple organ dysfunction syndrome. Blood 2003; 101:3765-3777
16. Aird WC: Vascular bed-specific hemostasis: Role of endothelium in sepsis pathogenesis. Crit Care Med 2001; 29(7 Suppl):S28-S35